共 91 条
- [1] Virani SS(2021)Heart disease and stroke statistics-2021 update: a report from the American Heart Association Circulation 143 e254-e743
- [2] Alonso A(2020)Global epidemiology and future trends of heart failure AME Med J 5 15-1186
- [3] Aparicio HJ(2019)Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 21 1169-651
- [4] Lippi G(2017)2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America J Cardiac Fail 23 628-334
- [5] Sanchis-Gomar F(2015)Entresto (sacubitril/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure Am Health Drug Benefits 8 330-810
- [6] Seferovic PM(2021)Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol. 77 772-1004
- [7] Ponikowski P(2014)Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-2288
- [8] Anker SD(2019)Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial Circulation 139 2285-548
- [9] Yancy CW(2019)Angiotensin-neprilysin inhibition in acute decompensated heart failure N Engl J Med 380 539-1048
- [10] Jessup M(2020)Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin–angiotensin system antagonists J Am Coll Cardiol 76 1034-380